Hôpital Cochin

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Obinutuzumab in Systemic Sclerosis

  NCT07842523· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status.

  NCT07888842· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Small Airway Dysfunction in Rheumatoid Arthritis and Systemic Sclerosis

  NCT07924124· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease

  NCT07827742· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

  NCT07705568· Phase 2· Eyevensys· Source

• Not yet recruiting

  Value of Biomarkers of Brain Injury for Predicting Psycho-cognitive Sequelae Secondary to Sepsis: a Prospective Multicenter Study

  NCT07746050· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  "Translating Articular Biomarkers Into Diagnoses"

  NCT06312943· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Implementing Low-dose ct Lung Cancer Screening in France.

  NCT07513818· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease

  NCT07627763· Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)· Source

• Recruiting

  Cognition and Patients With Lung Cancer

  NCT07160751· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss

  NCT07265505· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock

  NCT07345559· CMC Ambroise Paré· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.

  NCT07315347· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  " Development of Primary Cultures of Diaphragmatic Myoblasts for Basic Research Purposes "

  NCT07380308· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

  NCT06990659· University Hospital, Angers· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors

  2025-521034-28-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Recruiting

  StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

  NCT06767150· Phase 4· University Hospital, Toulouse· Source

• Recruiting

  Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients

  NCT06133426· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Active, not recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Nantes University Hospital· Source

• Not yet recruiting

  Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation

  NCT07029295· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· Phase 3· Grupo Espanol de Tumores Neuroendocrinos· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Involvement of General Practitioners in Lung Cancer Screening

  NCT06956040· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

  NCT06487078· Pfizer· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Recruiting

  Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

  NCT06582199· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer.

  NCT06348719· Rennes University Hospital· Source

• Recruiting

  Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA)

  NCT06083090· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source

• Recruiting

  Diagnostic and Prognostic Markers of Endometriosis in Menstrual Blood

  NCT06245512· Institut National de la Santé Et de la Recherche Médicale, France· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source

• Recruiting

  RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing

  NCT06195540· Phase 3· University Hospital, Angers· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

• Recruiting

  A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.

  2024-511309-47-00· Phase 2· Karyopharm Therapeutics Inc.· Source

• Recruiting

  Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

  NCT06712472· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.

  2023-506590-35-00· Phase 2· Centre Leon Berard· Source

• Recruiting

  FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

  NCT06393816· Phase 2· Centre Leon Berard· Source

• Recruiting

  Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

  NCT06553612· Centre Francois Baclesse· Source

• Recruiting

  Drugs Experience for Adolescents With Anorexia

  NCT06211517· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Karyopharm Therapeutics Inc· Source

• Recruiting

  Assessment of the Impact of Early Treatment for Anorexia Nervosa in a Day Hospital on Food Symptomatology, the Outcome of Young Patients, and the Family Experience

  NCT06218472· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  Fetal Cell Receptors Repertoire

  NCT06031714· Assistance Publique - Hôpitaux de Paris· Source

Showing 50 of 108.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer13 recruiting
• Neuroendocrine tumours5 recruiting
• Rheumatoid arthritis5 recruiting
• Systemic sclerosis (scleroderma)5 recruiting
• Childhood cancers4 recruiting
• Liver and biliary tract cancer4 recruiting
• COPD3 recruiting
• Endometrial cancer3 recruiting
• Endometriosis3 recruiting
• Sarcoma3 recruiting
• Ankylosing spondylitis2 recruiting
• Bronchiectasis2 recruiting
• Colorectal cancer2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Multiple myeloma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Osteoporosis2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Coeliac disease1 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Female infertility1 recruiting
• Hepatitis B1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Mild cognitive impairment1 recruiting
• Osteoarthritis1 recruiting
• Prostate cancer1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  Avoidant and Restrictive Food Intake Disorders (ARFID) in Adolescence: Early Oral Development, Psychopathological Profile and Sensory Integration

  NCT06665802· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease

  NCT04239196· Phase 2· Centre Hospitalier National D'Ophtalmologie Quinze-Vingts· Source

• Completed

  A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

  NCT06478706· Phase 2· Enterprise Therapeutics Ltd· Source

• Completed

  Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease

  NCT05533034· Assistance Publique - Hôpitaux de Paris· Source

• Withdrawn

  Comparison of the Effectiveness of a Web Fracture Liaison Service (e_FLS) to Fracture Liaison Services in France: the evAB Study (evAB)

  NCT05303350· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· ARCAGY/ GINECO GROUP· Source

• Terminated

  Study of ART0380 in Patients With Biologically Selected Solid Tumors

  NCT05798611· Phase 2· Artios Pharma Ltd· Source

• Completed

  Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

  NCT05944913· Centre Leon Berard· Source

• Completed

  Vamikibart in Participants With Uveitic Macular Edema

  NCT05642325· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

  NCT05424926· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Improving FAMily Members' Experience in the ICU

  NCT05461521· Nantes University Hospital· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Organon and Co· Source

• Completed

  Phenotyping of Chronic Pain in Diffused Systemic Scleroderma

  NCT05622578· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Multi-family Therapy and School Refusal: an Exploratory Study With Adolescents and Their Families

  NCT05432323· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Genmab· Source

• Completed

  Virtual Management of Rheumatoid Arthritis

  NCT05124782· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Hypnosis Intervention for the Management of Pain Perception During Joint Lavage

  NCT04547595· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis

  NCT04644471· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  Cystic Fibrosis Blood Neutrophils

  NCT04970225· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Disability Following Hospitalization in People of Working-age Surviving SARS-CoV-2 Infection - COVID-19

  NCT04724395· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

  NCT04842682· Phase 1· ANRS, Emerging Infectious Diseases· Source

• Completed

  Zephyr Etude Post-Inscription (French Registry)

  NCT04517916· Pulmonx Corporation· Source

• Completed

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· Phase 2· Verastem, Inc.· Source

• Terminated

  A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

  NCT04633447· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  NCT04111705· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Concept Medical Inc.· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· University Hospital, Montpellier· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  UTOLA: UTerin OLAparib

  NCT03745950· Phase 2· ARCAGY/ GINECO GROUP· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source

• Completed

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· ARCAGY/ GINECO GROUP· Source

• Completed

  Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

  NCT03606408· Phase 2· RECORDATI GROUP· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.

  NCT03164473· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

  NCT03401060· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

  NCT03249142· Phase 1/2· ARCAGY/ GINECO GROUP· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Hospices Civils de Lyon· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Groupe Francophone des Myelodysplasies· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)55 works · 8 trials
• COPD32 works · 6 trials
• Rheumatoid arthritis27 works · 9 trials
• Cystic fibrosis27 works · 4 trials
• Lupus (SLE)21 works · 4 trials
• Type 1 diabetes21 works · 0 trials
• Endometriosis20 works · 5 trials
• Bronchiectasis18 works · 2 trials
• Ankylosing spondylitis12 works · 3 trials
• Cushing's syndrome10 works · 3 trials
• ANCA-associated vasculitis9 works · 1 trial
• Dilated cardiomyopathy9 works · 0 trials
• Myelodysplastic syndromes7 works · 1 trial
• Duchenne muscular dystrophy7 works · 0 trials
• Antiphospholipid syndrome6 works · 1 trial
• Dermatomyositis and polymyositis (myositis)4 works · 1 trial
• Giant cell arteritis4 works · 2 trials
• Barrett's oesophagus3 works · 1 trial